Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger G Owen

Showing results (1-10 of 121) with videos related to

Pageof 13
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 14, 2021
Bruton Tyrosine Kinase Inhibitors in Waldenstrom Macroglobulinemia: Unprecedented Clinical Activity and Promising Future DirectionsRoger G Owen
Hemasphere|March 21, 2022
Minimal residual disease (mrd) in multiple myeloma: prognostic and therapeutic implications (including imaging)Roger G Owen
Seminars in Oncology|April 30, 2003
Developing diagnostic criteria in Waldenstrom's macroglobulinemiaRoger G Owen
Clinical Lymphoma|January 8, 2005
Monoclonal immunoglobulins and peripheral neuropathy: causative agent or coincidental finding?Roger G Owen
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2002
Extramedullary sites of involvement in hematologic malignancies: case 2. Lymphocyte morphology in splenic marginal zone lymphomaRoger G Owen
Cytometry. Part B, Clinical Cytometry|July 7, 2015
Better therapy requires better response evaluation: Paving the way for minimal residual disease testing for every myeloma patientOla Landgren, Roger G Owen
Leukemia & Lymphoma|January 21, 2012
Waldenstrom macroglobulinemia with a durable clinical response to epoetin betaChristopher Parrish, Roger G Owen
British Journal of Haematology|February 24, 2005
Minimal residual disease monitoring in multiple myeloma: flow cytometry is the method of choiceRoger G Owen, Andy C Rawstron
Blood Reviews|August 4, 2006
CNS prophylaxis in lymphoma: who to target and what therapy to useQuentin A Hill, Roger G Owen
Methods in Molecular Medicine|October 24, 2003
Fluorescent IgH fingerprinting to assess minimal residual disease in childhood B-lineage ALLPaul A S Evans, Roger G Owen
Pageof 13

Showing results (1-10 of 121) with videos related to

Sort By:
Pageof 13
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 14, 2021
Bruton Tyrosine Kinase Inhibitors in Waldenstrom Macroglobulinemia: Unprecedented Clinical Activity and Promising Future DirectionsRoger G Owen
Hemasphere|March 21, 2022
Minimal residual disease (mrd) in multiple myeloma: prognostic and therapeutic implications (including imaging)Roger G Owen
Seminars in Oncology|April 30, 2003
Developing diagnostic criteria in Waldenstrom's macroglobulinemiaRoger G Owen
Clinical Lymphoma|January 8, 2005
Monoclonal immunoglobulins and peripheral neuropathy: causative agent or coincidental finding?Roger G Owen
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2002
Extramedullary sites of involvement in hematologic malignancies: case 2. Lymphocyte morphology in splenic marginal zone lymphomaRoger G Owen
Cytometry. Part B, Clinical Cytometry|July 7, 2015
Better therapy requires better response evaluation: Paving the way for minimal residual disease testing for every myeloma patientOla Landgren, Roger G Owen
Leukemia & Lymphoma|January 21, 2012
Waldenstrom macroglobulinemia with a durable clinical response to epoetin betaChristopher Parrish, Roger G Owen
British Journal of Haematology|February 24, 2005
Minimal residual disease monitoring in multiple myeloma: flow cytometry is the method of choiceRoger G Owen, Andy C Rawstron
Blood Reviews|August 4, 2006
CNS prophylaxis in lymphoma: who to target and what therapy to useQuentin A Hill, Roger G Owen
Methods in Molecular Medicine|October 24, 2003
Fluorescent IgH fingerprinting to assess minimal residual disease in childhood B-lineage ALLPaul A S Evans, Roger G Owen
Pageof 13